Integrative multidisciplinary oncological approach in cancer patients receiving oncological treatments: a case series

Complementary and integrative medicine (CIM) practices are increasingly utilized by cancer patients to alleviate treatment-related side effects and support immune function. Among these, mycotherapy has gained attention for its potential hematologic and immunomodulatory benefits.

We report a retrospective observational case series of six cancer patients receiving standard oncologic therapy who were supplemented with a commercially available herbal preparation as part of routine integrative supportive care. Neutrophil count and patient-reported quality of life were monitored during standard clinical follow-up.

During supplementation, a temporal association was observed between integrative treatment and stabilization of neutrophil count, allowing continuation of anticancer therapy without further dose reductions or prolonged interruptions. No adverse events attributable to the supplement were recorded.

Although limited by its small sample size and observational design, this case series suggests that integrative mycotherapy may represent a feasible supportive approach in selected patients experiencing treatment-related hematologic toxicity.

In this case series study, neutrophil recovery was observed with a temporal association between the herbal preparation and the outcome. These findings should be interpreted as hypothesis generating. Prospective controlled studies are warranted to clarify efficacy, safety, and optimal integration strategies within standard oncology care.